Home › Upcoming votes › CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
Prior-year votes at CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. → 2025-2026 season, in the search
The deadline as the proxy statement states it: “Voting will be open until 11:59 pm EST on December 27, 2026”. Shares held through a bank, a broker or a company plan can have a different deadline; the voting instruction form says.
Read the proxy statement on EDGAR
Summary, checked against the proxy statement. Each point is backed by a passage of the filing, shown under the point; figures under “Last year’s votes” come from the company’s Form 8-K. Read the proxy statement before relying on it.
Annual meeting: five directors, say-on-pay, auditor ratification (Haynie & Company) and an evergreen amendment to the 2021 Equity Incentive Plan.
“will automatically increase on January 1, 2027 and on each subsequent January 1 through and including January 1, 2031, by up to 5% of the total number of shares of Common Stock issued and outstanding on December 31 of the immediately preceding calendar year” Find it in the filing
“is only 60,000 shares of Common Stock, of which 11,182 shares are the subject of outstanding option awards, with only 48,818 shares of Common Stock currently available for issuance for new awards under the Equity Plan.” Find it in the filing
“equal to the lesser of (A) five percent (5%) of the shares of Common Stock outstanding (on an as-converted, fully-diluted basis” Find it in the filing
“pursuant to which we purchased 4,000,000 shares of common stock of BioDefense, Inc. from CAC for an aggregate purchase price consisting of $200,000 in cash and 1,000,000 shares of our Common Stock.” Find it in the filing
“the Company and Mr. Warbington committed to make up to $500,000 and $100,000 of capital contributions, respectively, to Bionance, to fund Investments.” Find it in the filing
“Accordingly, in September 2026, the Sponsor returned the $125,000 capital contribution to the Company in exchange for the cancellation of the Company's interest in the Sponsor.” Find it in the filing
“Timothy Warbington, Donald Dickerson, Michael H. Finger, Susan Snow and Bruce S. Urdang as nominees for re-election to the Board of Directors at the Annual Meeting.” Find it in the filing
Ballot read from the proxy statement and checked. As listed in CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.’s proxy statement, with the board’s recommendation on each item.
| # | Item | Proposed by | Board recommends | Last year (same kind of item) |
|---|---|---|---|---|
| 1 | ELECTION OF DIRECTORS Director election |
Board | For | 5 nominees; support 88% to 91% |
| 2 | ADVISORY VOTE ON EXECUTIVE COMPENSATION Say on pay |
Board | For | 76% support |
| 3 | RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTANTS Auditor |
Board | For | — |
| 4 | APPROVAL OF AN AMENDMENT TO OUR 2021 EQUITY PLAN IMPLEMENTING THE EVERGREEN PROVISION | Board | For | — |
From CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.’s Form 8-K, filed December 19, 2025, for the meeting held December 18, 2025 (read it on EDGAR). Support is the share of votes cast that were FOR: abstentions and broker non-votes are left out.
| Item | Support (of votes cast) | Reported outcome |
|---|---|---|
| Elect Director: Timothy Warbington | 91% | — |
| Elect Director: Donald Dickerson | 91% | — |
| Elect Director: Michael H. Finger | 89% | — |
| Elect Director: Susan Snow | 88% | — |
| Elect Director: Bruce S. Urdang, Esq. | 88% | — |
| Proposal II - The compensation of the Company's named executive officers was approved as follows: | 76% | Approved |
| Proposal III –The ratification of the appointment of Haynie & Company was approved as follows: | 92% | Approved |
The meeting facts and ballot come from the SEC proxy filings listed above. Ballots are read from the proxy statement and checked against the filing’s own text; when that check does not pass, the page shows “see the proxy statement” instead of a ballot. Last year’s figures are the company’s official Form 8-K results and the managers’ Form N-PX reports. Nothing on this page predicts how any shareholder will vote, and it is not investment advice. How this works.